Navigation Links
WuXi PharmaTech Announces Second-Quarter 2009 Results
Date:8/11/2009

GAAP measures in assessing our financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. We expect to continue providing gross profit, operating income, and net income on a non-GAAP basis using a consistent method on a quarterly basis.

You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, anticipated full-year, second-half, and third-quarter 2009 operating results (including estimated total net revenues, China-based Laboratory Services net revenues, Manufacturing Services net revenues, adjusted EBITDA, gross margins, and other trends), planned capital expenditure and investment levels, and the anticipated benefits of those efforts and the planned expansion of our service offerings and areas of related revenue growth.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
2. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
3. WuXi PharmaTech Receives Award from BASF
4. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
5. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
6. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
7. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
8. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
9. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
10. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
11. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... and NYSE: SNY) today announced that the Companies intend ... rare pediatric disease priority review voucher in connection with ... priority review voucher entitles the holder to designate a ... 6-month review from the filing date instead of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears are ... Academy of Dermatology (Academy) in an effort to raise ... Bears will host free SPOT me™ skin cancer screenings ... at Soldier Field. SPOT me™ is an educational ... the dangers and risks of skin cancer, and encourages ...
(Date:7/30/2014)... July 30, 2014 Sales Horizons, a ... of blended sales training programs for companies engaged in ... programs used by thousands of salespeople over 25 years ... training program can be customized to address the unique ... blended sales training program consists of two ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... in Industrial Applications , the global market for industrial ... by 2018, registering a five-year compound annual growth rate ... recorded in the detergent enzyme segment with a CAGR ... has influenced almost every sector of industrial activity, ranging ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3
... (NYSE: SGP ) announced that Nippon Organon ... Drug Application with the Japanese,Ministry of Health, Labour ... selective relaxant binding agent (SRBA), sugammadex., Sugammadex ... the effects of certain muscle relaxants, rocuronium bromide,(marketed ...
... The Science and Technology Foundation of,Japan announced the ... Japan,Prize today., All three laureates this year ... and Dr. Robert Elliot Kahn who received their ... for the,Internet" in the prize category of "Information ...
... Both Clinical Trial Experience and Business ... CAMBRIDGE, Mass., Jan. 16 Cytel, Inc. ... Irving Dark has,accepted the role of Vice President ... Cytel 15-years of management experience guiding drug,biologic and ...
Cached Biology Technology:Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 2Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 3American Scientists Named as Laureates of the 2008 (24th) Japan Prize 2Irving Dark Named Vice President of Cytel Clinical Research Services 2
(Date:7/30/2014)... in female baboons suggests that the route to a higher ... have lots of supportive sisters. , A female baboon,s social ... the rank of her mother - the higher the mother ... reason, dominance rank in female baboons is thought to be ... a good spot in the pecking order, whereas females born ...
(Date:7/30/2014)... could be as simple as inserting a medicated, disappearing ... Washington bioengineers have discovered a potentially faster way to ... HIV. Their method spins the drug into silk-like fibers ... higher doses of the drug than possible with other ... could offer women a potentially more effective, discreet way ...
(Date:7/30/2014)... ranges and a changing climate threaten some of ... and so conservationists establish seed collections to save ... hopes of preserving some genetic diversity., For decades, ... models that offer a one-size-fits-all approach for how ... 50 seed samples regardless of species, pollination mode, ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3Saving seeds the right way can save the world's plants 2
... global carbon cycle, helping sequester significant amounts of carbon. ... that they discolor coastal waters and reduce the amount ... known as "red tide," the term "harmful algal blooms" ... of algal biomass can sometimes also turn the ocean ...
... of scientists studying genetic pathways that are mutated in ... forms of congenital heart disease including hypertrophic cardiomyopathy ... the leading cause of sudden death in children and ... and successfully treated HCM in the lab. ...
... Massachusetts Institute of Technology biologist Graham Walker leads a ... recreate the creativity and excitement of his research lab: ... MIT colleagues to identify new research questions in science ... Walker will talk about his experiences running a science ...
Cached Biology News:Brown tide culprit sequenced: Genome of the first of algal bloom species 2Brown tide culprit sequenced: Genome of the first of algal bloom species 3Brown tide culprit sequenced: Genome of the first of algal bloom species 4Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Plenary speech by HHMI professor highlights efforts of scientist-educators 2Plenary speech by HHMI professor highlights efforts of scientist-educators 3
... Translation System is ideal for both radioactive ... Translation System: Provides five pre-mixed nucleotide ... Yields >10 8 cpm/g control ... to monitor the performance of the system ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
Biology Products: